Market cap
$6,731 Mln
Recently Viewed
Clear AllMarket cap
$6,731 Mln
Revenue (TTM)
$22 Mln
P/E Ratio
--
P/B Ratio
16.7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-6.5
Debt to Equity
0.2
Book Value
$7.2
EPS
$-4.1
Face value
--
Shares outstanding
58,479,812
CFO
$-0.26 Mln
EBITDA
$-387.89 Mln
Net Profit
$-370.78 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arcellx Inc (ACLX)
| 76.5 | 0.4 | 68.9 | 78.3 | 39.2 | -- | -- |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Arcellx Inc (ACLX)
| -15.0 | 37.8 | 79.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arcellx Inc (ACLX)
|
115.1 | 6,731.2 | 22.3 | -228.9 | -918.3 | -53.4 | -- | 16.7 |
| 75.3 | 9,876.5 | 1,091.0 | 202.3 | 31.6 | 31.3 | 44.1 | 17.3 | |
| 64.3 | 7,402.1 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.1 | 11,351.6 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 87.4 | 11,058.0 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.1 | 7,471.0 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.6 | 155.0 | |
| 518.1 | 11,956.1 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.9 | |
| 418.6 | 11,812.0 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26 | 19.7 | |
| 99.3 | 7,826.7 | 0.0 | -425.4 | -- | -36.7 | -- | 6.3 | |
| 327.8 | 9,001.1 | 0.0 | -303.3 | -- | -45.8 | -- | 10.2 |
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel,... which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. As of April 28, 2026, Arcellx, Inc. operates as a subsidiary of Gilead Sciences, Inc. Address: 800 Bridge Parkway, Redwood City, CA, United States, 94065 Read more
Chairman of the Board, CEO & President
Mr. Rami Elghandour
Chairman of the Board, CEO & President
Mr. Rami Elghandour
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Arcellx Inc (ACLX) is $115.07 (NASDAQ) as of 29-Apr-2026 09:30 EDT. Arcellx Inc (ACLX) has given a return of 39.18% in the last 3 years.
Since, TTM earnings of Arcellx Inc (ACLX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-15.95
|
9.07
|
|
2024
|
-38.58
|
9.11
|
|
2023
|
-37.69
|
5.49
|
|
2022
|
-5.91
|
5.44
|
|
2021
|
--
|
--
|
The 52-week high and low of Arcellx Inc (ACLX) are Rs 115.13 and Rs 47.86 as of 01-May-2026.
Arcellx Inc (ACLX) has a market capitalisation of $ 6,731 Mln as on 29-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Arcellx Inc (ACLX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.